speaker-icon

Latest Posts

Partex-NV-announces-collaboration-with-Althea-DRF-Lifesciences

28

Mar 24

Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF...
Read More
Partex-Group-presents-results-from-a-pilot-project-with-AIO

18

Mar 24

Innovative AI technology in oncology: Partex Group presents results from a pilot project

During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
catana-pr

Catana Capital: New collaboration with Life Science AI pioneer Innoplexus

Catana Capital partners with a leading provider of AI solutions in the Life Science sector

Frankfurt am Main, December 16, 2019: As a pioneer in the application of Big Data and AI for quantitative asset management, Catana Capital is always open to collaborate with other innovators in the space in order to develop new innovative investment strategies. After a successful first year of the Data Intelligence Fund and the recent launch of overlay strategies for institutional investors, Catana Capital has now partnered with Innoplexus, a leading provider of artificial intelligence solutions in the Life Science sector.

Innoplexus has proven to provide deep insights into the Life Sciences data universe and especially the assessment of outcomes of clinical trials, which, combined with Catana Capital“s know how and experience in quantitative asset management, will form the basis for a successful joint venture. Innoplexus“ proprietary use of artificial intelligence and machine learning fits perfectly into Catana Capital“s strategy to further scale its revolutionary new investment strategy based on independent trading signals in the area of European pharmaceutical equities, where both companies will work together on an exclusive basis.

Catana Capital“s innovative Data Intelligence Fund (ISIN: DE000A2H9A76) has met all expectations since its launch and the additional approach into the pharma sector is a solid diversification within the fund which will further contribute to its success.

Catana Capital GmbH is a financial services institution licensed in compliance with Section 32 of the German Banking Act (KWG) and domiciled in Frankfurt am Main. The FinTech was founded in August 2015 and manages the Data Intelligence Fund, a public fund based entirely on big data and artificial intelligence. Catana Capital sees itself as a pioneer in the development of new approaches to asset management and offers innovative investment products for private investors and institutional clients.

Further information can be found at https://catanacapital.com/

Originally published on Press Network.

Featured News

new_app_cancer_patients

New app for cancer patients

Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…